NSN Co. Ltd (031860) - Total Liabilities

Latest as of December 2025: ₩20.47 Billion KRW ≈ $13.87 Million USD

Based on the latest financial reports, NSN Co. Ltd (031860) has total liabilities worth ₩20.47 Billion KRW (≈ $13.87 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

NSN Co. Ltd - Total Liabilities Trend (2006–2025)

This chart illustrates how NSN Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See 031860 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

NSN Co. Ltd Competitors by Total Liabilities

The table below lists competitors of NSN Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
MENNICA SKARB.AB ZY -10
F:98S
Germany €112.39 Million
Park Ha Biological Technology Co., Ltd.
NASDAQ:BYAH
USA $1.58 Million
Embelton Ltd
AU:EMB
Australia AU$14.14 Million
Jasper Therapeutics Inc
NASDAQ:JSPR
USA $17.78 Million
Sahathai Terminal Public Company Limited
BK:PORT
Thailand ฿1.74 Billion
Tectona
TA:TECT
Israel ILA7.16 Million
4Imprint Group Plc
LSE:FOUR
UK GBX120.30 Million
Frigo-Pak Gida Maddeleri Sanayi ve Ticaret AS
IS:FRIGO
Turkey TL839.63 Million

Liability Composition Analysis (2006–2025)

This chart breaks down NSN Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 031860 market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.52 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.92 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.50 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how NSN Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for NSN Co. Ltd (2006–2025)

The table below shows the annual total liabilities of NSN Co. Ltd from 2006 to 2025.

Year Total Liabilities Change
2025-12-31 ₩20.47 Billion
≈ $13.87 Million
+154.73%
2024-12-31 ₩8.03 Billion
≈ $5.45 Million
+26.86%
2023-12-31 ₩6.33 Billion
≈ $4.29 Million
-72.87%
2022-12-31 ₩23.35 Billion
≈ $15.82 Million
-11.64%
2021-12-31 ₩26.42 Billion
≈ $17.91 Million
+158.38%
2020-12-31 ₩10.23 Billion
≈ $6.93 Million
-77.59%
2019-12-31 ₩45.63 Billion
≈ $30.92 Million
+270.74%
2018-12-31 ₩12.31 Billion
≈ $8.34 Million
+1.36%
2017-12-31 ₩12.14 Billion
≈ $8.23 Million
-47.36%
2016-12-31 ₩23.07 Billion
≈ $15.63 Million
+50.33%
2015-12-31 ₩15.34 Billion
≈ $10.40 Million
+79.01%
2014-12-31 ₩8.57 Billion
≈ $5.81 Million
-22.07%
2013-12-31 ₩11.00 Billion
≈ $7.45 Million
-88.26%
2012-12-31 ₩93.66 Billion
≈ $63.47 Million
+62.32%
2011-12-31 ₩57.70 Billion
≈ $39.10 Million
+77.05%
2010-12-31 ₩32.59 Billion
≈ $22.08 Million
+286.94%
2007-12-31 ₩8.42 Billion
≈ $5.71 Million
-28.26%
2006-12-31 ₩11.74 Billion
≈ $7.96 Million
--

About NSN Co. Ltd

KQ:031860 Korea Diagnostics & Research
Market Cap
$12.68 Million
₩18.71 Billion KRW
Market Cap Rank
#26451 Global
#1944 in Korea
Share Price
₩693.00
Change (1 day)
+17.26%
52-Week Range
₩265.00 - ₩1221.00
All Time High
₩146500.00
About

DHX Company Co., Ltd. engages in biomedical and distribution businesses in South Korea. The company offers Microbiome to treat intractable skin diseases; REJURUB; and AI digital brain diagnostic device. It also purchases and distributes IT components, including graphics cards, DRAM, CPUs, high-capacity storage, and multi-purpose displays; import and distribution of cosmetics; f and b distribution… Read more